J. Mark Sloan MD
Associate Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7520mark.sloan@bmc.org
sloanjm@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Factotum hematologist at Boston Medical Center
Associate Professor at Chobanian and Avedisian School of Medicine.
Program director for the hematology/oncology fellowship at Boston University.
I see patients with a variety of benign and malignant blood disorders.
I have particular research interests in AL Amyloidosis, HTLV-1 associated leukemia/lymphoma (ATLL)
Education
Medicine-Internal, MD, Yale University School of Medicine
Physics, BS, Haverford College
Publications
Sofoluwe A, Ferri G, Sloan JM, Caron J, Thomasson RR. Implementation of a Duffy antigen screening test order with interpretation guide to help optimize resource allocation at an urban safety-net hospital. Transfusion. 2025 Mar 07. PMID: 40055154.
Published on 12/10/2024Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
Published on 11/26/2024Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.
Published on 11/22/2024Reifler KA, Francoeur Smith T, Bodanapu G, Fagan M, Bourque DL, Sloan JM. Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston. Leuk Res Rep. 2024; 22:100489. PMID: 39659827.
Published on 9/3/2024Hibbs SP, Aiken L, Vora K, Mowete C, Merz LE, Apea V, Sloan JM, Lathan CS, Abel GA, Hantel A. Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA Netw Open. 2024 Sep 03; 7(9):e2432475. PMID: 39259539.
Published on 3/11/2024Zheng R, Solomon A, DiLorenzo M, Rajendran I, Park J, Dhongade V, Garcia MA, Eberhardt RT, Sloan JM, Weinberg J, Klings ES. The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Adv Hematol. 2024; 2024:8838308. PMID: 38500844.
Published on 8/20/2023Sarosiek S, Lee MH, Doros G, Edwards CV, Quillen K, Brauneis D, Shelton AC, Sanchorawala V, Sloan JM. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Transplant Cell Ther. 2023 Nov; 29(11):695.e1-695.e7. PMID: 37607644.
Published on 6/6/2023Halpin M, Lerner A, Sagar M, Govender P, Shah B, Weinberg J, Sarosiek S, Sloan JM. A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19. medRxiv. 2023 Jun 06. PMID: 37333402.
Published on 6/1/2023Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.
Published on 5/8/2023Freydman J, Staron A, Hughes D, Sloan JM. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome. J Oncol Pharm Pract. 2023 Sep; 29(6):1489-1493. PMID: 37157792.
Media Mentions
Published on 6/19/2020
Older Adults May Be Left Out of Some Covid-19 Trials
View full list of 1 media mentions.